Patel, Saagar N.
Lee, Charles
Cui, David
Wingert, Andreas M.
Zhou, Shouhao
Scott, Ingrid U.
Article History
Received: 22 June 2021
Revised: 26 August 2021
Accepted: 30 September 2021
First Online: 18 October 2021
Declarations
:
: This study was deemed exempt from further review by the Penn State College of Medicine Institutional Review Board.
: Dr. Scott serves as Principal Investigator and Chair of the <i>S</i>tudy of <i>CO</i>mparative Treatments in <i>RE</i>tinal Vein Occlusion <i>2</i> (SCORE2) trial, which is funded by the National Eye Institute, has served as a consultant for Regeneron, and has served on the Data and Safety Monitoring Committee for clinical trials sponsored by Novartis (these disclosures are unrelated to the present work). None of the other authors report any financial disclosures or financial conflicts of interest.